Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia.

TO THE EDITOR: Covalent Bruton tyrosine kinase inhibitors (cBTKis) are commonly used targeted agents in early lines of therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); however, treatment following disease progression on cBTKis remains a challenge in clinical practice. Venetoclax is a B-cell lymphoma-2 inhibitor approved for CLL and SLL treatment, either as continuous monotherapy or as a fixed-treatment duration (FTD) regimen in combination with anti-CD20 antibodies (FTD Ven+anti-CD20; frontline, 12 months; relapsed/refractory, 24 months). Venetoclax has demonstrated durable responses and outcomes among patients with previous cBTKi exposure, both in clinical trials (eg, M14 032 and VENICE-1)6,7 and in real-world studies.

Authors

Institutions

Publication Details

Journal
UNC Libraries
Published
2026-11-17
DOI
https://doi.org/10.17615/63cv-5w58
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia.

Frederick Lansigan, Isabelle Fleury, Andrés Chang, Brian Thomas Hill et al.
2 links
UNC Libraries
Chronic Lymphocytic Leukemia Research
article

Fixed-treatment duration venetoclax following covalent BTKi progression in chronic lymphocytic leukemia.

Frederick Lansigan, Isabelle Fleury, Andrés Chang, Brian Thomas Hill, Nicole Lamanna, Alan Pierre Zausner Skarbnik, Catherine Callaghan Coombs, Deborah Marie Stephens, Nicolás Martínez‐Calle, Lindsey Elizabeth Roeker, Paul M. Barr, Joanna Meehan Rhodes, Matthew Steven Davids, Meghan C. Thompson, Hande H. Tuncer, Beenish S. Manzoor, Christopher Edward Jensen, Bita Fakhri, Jennifer R. Brown, Mazyar Shadman, Nilanjan Ghosh, Laurie Pearson, Irina PIVNEVA, Michael Coyle, Stephen J Schuster, Chaitra Ujjani, Yun Choi, Nnadozie Emechebe, Wendy Sinai, Lori A Leslie, Nancy Kaddis, Toby A Eyre, Annie Guerin
article en

Abstract

TO THE EDITOR: Covalent Bruton tyrosine kinase inhibitors (cBTKis) are commonly used targeted agents in early lines of therapy for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL); however, treatment following disease progression on cBTKis remains a challenge in clinical practice. Venetoclax is a B-cell lymphoma-2 inhibitor approved for CLL and SLL treatment, either as continuous monotherapy or as a fixed-treatment duration (FTD) regimen in combination with anti-CD20 antibodies (FTD Ven+anti-CD20; frontline, 12 months; relapsed/refractory, 24 months). Venetoclax has demonstrated durable responses and outcomes among patients with previous cBTKi exposure, both in clinical trials (eg, M14 032 and VENICE-1)6,7 and in real-world studies.

UNC Libraries
University of North Carolina at Chapel Hill (US)
Good health and well-being
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon